Matt Hoffman, Editorial Director for NeurologyLive, has covered medical news for MJH Life Sciences, NeurologyLive’s parent company, since 2017. He executive produces the NeurologyLive Mind Moments® podcast, and hosted the Medical World News show Deep Dive. Follow him on Twitter @byMattHoffman or email him at mhoffman@neurologylive.com
Roche Gets FDA Clearance for CSF Beta-Amyloid and Phospho-Tau Alzheimer Disease Assays
December 9th 2022The Elecsys pTau181 and Abeta42 cerebrospinal fluid assays achieved 90% concordance with amyloid PET scans, according to Roche’s announcement. The assays are approved for use with the cobas fully automated immunoassay analyzers.
Chronic ASM Use Associated With Acute Symptomatic Seizures in Patients With Stroke
December 6th 2022Retrospective analysis of a group of individuals with stroke suggests that nonconvulsive acute symptomatic seizures are associated with long-term use of antiseizure medications, providing key data in guiding therapy use in this population.
The Advantages of Multidisciplinary Care and APP Incorporation in Epilepsy
December 6th 2022Lucretia Long, APRN-CNP, an associate clinical professor of neurology at OSU Wexner Medical Center, offered her perspective on the benefits of having multiple specialists available to provide comprehensive care to patients.
Transition to Adult Care Is Inconsistent for Patients With Dravet Syndrome, Survey Suggests
December 4th 2022A survey conducted in conjunction with the Dravet Syndrome Foundation suggests that many patients with DS do not undergo the transition of care from pediatric to adult neurology providers, with caregivers of those who did expressing some concerns about the process.
Wide Variety Exists for First Antiseizure Medication Prescriptions in Children With Epilepsy
December 4th 2022Data from the Pediatric Epilepsy Learning Healthcare System suggest that a variety of factors—including age, preference, insurance, and demographics—affect physician selection of antiseizure medications, with little standardization among this population.
New Prospective Data on Patients With Dravet Syndrome Inform Outcome Measurements in Trials
December 3rd 2022Data from the BUTTERFLY study of 36 children with Dravet syndrome have provided 12-month measurements of neurodevelopment, clinical status, quality of life, and executive function. Investigators expressed that these data will help inform future trial outcome measures.
Treating NMOSD Early in the Disease Course: Inebilizumab’s Efficacy in N-MOmentum
November 26th 2022Bruce Cree, MD, PhD, MAS, FAAN, offered his perspective on data from the phase 2/3 N-MOmentum trial of the recently approved inebilizumab (Uplizna; Horizon Therapeutics) and why the therapy stands out from other NMOSD treatments.
Episode 76: ECTRIMS 2022 and the Latest in MS Advances
November 4th 2022Mind Moments®, a podcast from NeurologyLive®, brings you exclusive interviews with Darin Okuda, MD; Federica Picariello, PhD; Brenda Banwell, MD; Riley Bove, MD; Tomas Kalincik, MD, PhD; and Marisa McGinley, DO. [LISTEN TIME: 34 minutes]
Palatability Strategies Show Promise for Addressing AMX0035 Taste Concerns Among Patients With ALS
November 2nd 2022As patients with ALS may have altered taste perception and have expressed that bitterness is associated with AMX0035 (Relyvrio; Amylyx) administration, a number of coping strategies have suggested a workaround to ensure treatment adherence and effectiveness.
Nondisabling MS Relapses Associated With Higher Disability Accumulation
October 28th 2022In a late-breaking presentation in ECTRIMS, data from the MSBase international registry was suggestive of higher disability accumulation risk compared with those who did not experience relapse, in both treated and untreated patients with MS.
Cladribine Shows Efficacy, Tolerability Among Patients With MS Switching From Infusion DMTs
October 26th 2022In a small real-world cohort, annualized relapse rates were reduced for patients with multiple sclerosis who switched to cladribine (Mavenclad; EMD Serono) from ocrelizumab (Ocrevus; Genentech), natalizumab (Tysabri; Biogen), and alemtuzumab (Lemtrada; Sanofi Genzyme).
NeurologyLive® Brain Games: October 23, 2022
October 23rd 2022Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is the history of the European Committee for Treatment and Research in Multiple Sclerosis.